Research location

Apolda

Germany

Published trials8
Site observations9
Linked trials published8
Page1 / 1
Advertisement

Research activity in Apolda

Germany

CureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 9 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Apolda

8 linked trials · page 1 of 1
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanNCT05573893 · 2023-09-12 · 1 site observation
RECRUITING
Azilect® In Wearing-Off (AIWO)NCT02384512 · 2014-01-01 · 1 site observation
COMPLETED
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPDNCT01285180 · 2010-08-01 · 1 site observation
COMPLETED
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical PracticeNCT00505388 · 2007-07-01 · 1 site observation
COMPLETED
Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's DiseaseNCT00539214 · 2007-03-01 · 1 site observation
COMPLETED
Local Phase 4 Pan-European SMART StudyNCT00463866 · 2007-03-01 · 1 site observation
COMPLETED
Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk HypertensivesNCT00539487 · 2007-01-01 · 2 site observations
COMPLETED
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.